🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Guide to writing a specific aims page for a grant application

Some thoughts on the fantastic DARS trial. It’s invigorating to see a randomized trial of radiation technique, which can have such an impact on the patient in the short- and long-term. thelancet.com/journals/lanon…

Thrilled to see our INRT-AIR trial out in press! In this phase II study, we **eliminated** elective nodal irradiation for patients with HSNCC treated with definitive RT/CRT. aacrjournals.org/clincancerres/…

Prophylactic RT Versus SOC for High-Risk Asymptomatic Bone Metastases Multicenter, Randomized Phase II Clinical Trial N=78, 122 high risk asymptomatic bone mets 1:1 SOC vs SOC + RT ⬇️ SRE ⬇️ admissions ⬆️ OS HR 0.49 (0.27 to 0.89) P = .018 🤩 ascopubs.org/doi/10.1200/JC…

David Sher presents late breaking abstract DARTBOARD, Randomized trial of adaptive H&N #radiotherapy using 1mm margin. ➡️ Feasibility demonstrated. PRO improvement observed. ➡️ Nice use of advanced #radonc techniques! 👏🏽👏🏽 💰Cost-effectiveness analysis needed?

🚨🚨🚨PREOPANC-2 dropped! For AR or BR-PDAC, neoadjuvant FFX and neoadjuvant Gemcitabine based CRT (36 Gy/15 fx) had comparable outcomes. mOS was 21.9 m with FFX arm vs 21.3 m with CRT (HR 0.87; 95% CI 0.68-1.12, p=0.28), and similar resection rates 77% vs. 75%. #ESMO23

🚨🚨🚨SANO-trial!! Been waiting for this one! Patients with esophagus ACA with cCR after CRT randomized to active surveillance vs. esophagectomy ✅Non-inferior OS and improved QoL with AS approach! This is 🔥🔥🔥 Looking forward to manuscript to unpack the details #ESMO23

Anal cancer staging as fast as possible AJCC American Cancer Society National Cancer Institute

A very impressive study for #AI picking up pancreatic cancer from non-contrast CT with 93% sensitivity, 99.9% specificity, AUC ~0.99, including from chest CT scans performed Covid. nature.com/articles/s4159… Nature Medicine

Perhaps I’m tipping over a sacred (H&N contouring) cow, but… Why do we need 5 mm around the GTV for CTV70? Let’s have PTV70 = GTV70 plus setup error. Use a lower dose CTV for microscopic dz. Why? Almost all recurrences are directly in-field (1/2)

Inspired by a recent discussion on twitter/X about a trial- here’s a thread about the importance of intent to treat analysis, and the caveats/shortcomings of per-protocol or analysis per “compliance/adherence”. Buckle yourself up for an educational 🧵

Very useful, large, study on ORN after extractions preceding H&N radiotherapy (n=879) from PMH. Some comments: 1. Overall risk was quite low (n=16, 1.8% ORN out of entire cohort), about 1/3 successfully treated within 6 months. (1/n)

There are "known unknown" and "unknown unknown" p16+ squamous cell carcinomas of the head & neck. For patients with HPV+ SqCC of the upper neck, it is an oropharynx primary unless proven otherwise, with mucosal coverage as indicated (can debate NP coverage too)... (1/3)

1/N Finally out!! -- 30Gy for HPV+OPC in Journal of Clinical Oncology – work by the Memorial Sloan Kettering Cancer Center Head and Neck team, led by Nancy Lee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

🚨🚨🚨 Rectal Cancer Tweetorial!! Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management! #GI24 #GIonc #RadOnc Thank you ASCO for the opportunity!🙏🏽 1/

This trial is insane in every good way imaginable. Insanely innovative, insanely different from standard-of-care, insanely successful. A few thoughts below.

🚨🚨🚨 #ESOPEC🚨🚨🚨 🔥Practice shifting trial🔥 Patients with resectable, locally advanced, esophagus/GEJ adenocarcinoma Randomized Peri-op FLOT (FLOT4) vs Pre-operative chemoradiation (CROSS) Congrats to the study investigators! Let’s dive in! #ASCO24 Mayo Clinic Radiation Oncology 1/

🚨📢Happening now - HN oral abstracts #ASCO24‼️ PRACTICE CHANGING trial of hypoxia directed major radiation de-escalation as definitive treatment for HPV+OPC by Nancy Lee Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center, showing that 30Gy+Chemo is sufficient for cure, with > 500 pts treated so far.

Absolutely terrific thread here on ENI dosing for oropharyngeal cancer, touching not just on recent data but on how new standards are established. Just a few thoughts on top of well-articulated arguments for different approaches. (1/n)

Very exciting to finally see these data. I think this box is critical to interpret the results... essentially all of the benefit is in treating micrometastatic disease. Some brief thoughts: